论文部分内容阅读
目的:了解厄贝沙坦逆转原发性高血压早期肾损害、降压作用的有效性和安全性,并与福辛普利比较。方法:128例轻、中度EH患者,随机分为厄贝沙坦治疗组及福辛普利治疗组各64例,分别给予厄贝沙坦组0.15 g/d和福辛普利组10 mg/d,随访并记录不良反应12周后行相关检查与服药前比较并两组比较。结果:厄贝沙坦组、福辛普利组血压有明显下降。结论:逆转早期肾脏损害厄贝沙坦优于福辛普利。
Objective: To investigate the efficacy and safety of irbesartan in reversing the effects of early renal damage and antihypertensive effect in patients with essential hypertension and to compare with fosinopril. Methods: A total of 128 patients with mild or moderate EH were randomly divided into irbesartan-treated group and fosinopril-treated group (n = 64). The patients were treated with irbesartan 0.15 g / d and fosinopril 10 mg / d, followed up and recorded adverse reactions 12 weeks after the relevant checks and compared before taking the two groups were compared. Results: The irbesartan group, fosinopril group significantly decreased blood pressure. CONCLUSIONS: Irbesartan is superior to fosinopril in reversing early renal impairment.